Contact Us Today to Learn More
Conclusions This open-label, single-center pilot study suggests that GLP-1-RAs are an effective and safe treatment option for achieving significant weight loss with a favorable effect on headache, leading to reduced acetazolamide dosage in pwIIH
Average responders (~60% of patients): Weight loss of 23 kg over 6 months, plateauing thereafter
que si el tratamiento con GLP-1 ya estaba establecido, es posible comenzar con la dosis de mantenimiento del nuevo medicamento, sin necesidad de utilizar las dosis de inicio
Acetaminophen was dissolved in ethanol and set to a final concentration of 1 mM in the growth medium
It facilitates the consultation, coordinates prescriptions, and manages the overall experience, including ongoing support and medication tracking